Regenerative Medicine Company Announces Q1 2024 Net Sales

Celularity Forecasts Strong Sales for Q1 and Full Year 2024, Reiterates Biomaterial Pipeline.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

Celularity Inc. (NASDAQ: $CELU), a pioneer in the field of regenerative medicine, recently announced its sales expectations for the first quarter of 2024 and the entire fiscal year. The company also reiterated…